Vivus maintained at outperform by RBC

Vivus Inc. was kept at outperform, speculative risk, by RBC Capital Markets analyst Ken Trbovich with a $6.00 price target after MUSE sales were higher than expected. However, because of unpredictable order patterns, RBC said it does not believe that this changes the outlook for the year. Vivus reported MUSE sales of $3.3 million compared to an estimate of $800,000. Shares of the Mountain View, Calif.-based pharmaceutical company were up 4 cents, or 1.21%, at $3.34. (Nasdaq: VVUS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.